IS6925A - Aðferð og skömmtunarform til meðhöndlunar æxla með gjöf tegafúrs, úracíls, fólínsýru, paclítaxels og karbóplatíns - Google Patents

Aðferð og skömmtunarform til meðhöndlunar æxla með gjöf tegafúrs, úracíls, fólínsýru, paclítaxels og karbóplatíns

Info

Publication number
IS6925A
IS6925A IS6925A IS6925A IS6925A IS 6925 A IS6925 A IS 6925A IS 6925 A IS6925 A IS 6925A IS 6925 A IS6925 A IS 6925A IS 6925 A IS6925 A IS 6925A
Authority
IS
Iceland
Prior art keywords
tegafur
carboplatin
paclitaxel
uracil
tumors
Prior art date
Application number
IS6925A
Other languages
English (en)
Inventor
A. Ajani Jafferhusen
E. Benner Steven
S. Dugan Terry
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of IS6925A publication Critical patent/IS6925A/is

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
IS6925A 2001-03-06 2003-08-22 Aðferð og skömmtunarform til meðhöndlunar æxla með gjöf tegafúrs, úracíls, fólínsýru, paclítaxels og karbóplatíns IS6925A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27357701P 2001-03-06 2001-03-06
PCT/US2002/006262 WO2002076459A1 (en) 2001-03-06 2002-03-04 Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin

Publications (1)

Publication Number Publication Date
IS6925A true IS6925A (is) 2003-08-22

Family

ID=23044526

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6925A IS6925A (is) 2001-03-06 2003-08-22 Aðferð og skömmtunarform til meðhöndlunar æxla með gjöf tegafúrs, úracíls, fólínsýru, paclítaxels og karbóplatíns

Country Status (20)

Country Link
US (1) US6770653B2 (is)
EP (1) EP1368034A1 (is)
JP (1) JP2005506294A (is)
KR (1) KR20030081496A (is)
BR (1) BR0207443A (is)
CA (1) CA2439676A1 (is)
CZ (1) CZ20032266A3 (is)
EE (1) EE200300429A (is)
HR (1) HRP20030801A2 (is)
HU (1) HUP0303466A3 (is)
IL (1) IL157357A0 (is)
IS (1) IS6925A (is)
MX (1) MXPA03007989A (is)
NO (1) NO20033910L (is)
PL (1) PL363967A1 (is)
RU (1) RU2284184C2 (is)
SK (1) SK10602003A3 (is)
WO (1) WO2002076459A1 (is)
YU (1) YU69903A (is)
ZA (1) ZA200306541B (is)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1365808T3 (da) * 2000-11-06 2011-05-16 Pharma Mar Sa Sammensætninger til antitumorbehandling indeholdende ecteinascidin 743
US9611227B2 (en) 2003-03-14 2017-04-04 Taiho Pharmaceutical Co., Ltd. Antitumor effect potentiator and antitumor agent
WO2004087105A1 (en) * 2003-04-02 2004-10-14 Celator Pharmaceuticals, Inc. Combination formulations of platinum agents and fluoropyrimidines
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
EP1691809A1 (en) * 2003-11-14 2006-08-23 Pharma Mar, S.A. Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
KR20050099311A (ko) * 2004-04-09 2005-10-13 에이엔에이치 케어연구소(주) 주사제용 항암제 조성물
ATE430586T1 (de) * 2004-10-26 2009-05-15 Pharma Mar Sa Pegyliertes liposomales doxorubicin in kombination mit ecteinescidin 743
DK1658848T3 (da) 2004-10-29 2007-11-26 Pharma Mar Sa Formuleringer omfattende ecteinascidin og et disaccharid
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
LT3248600T (lt) 2005-02-18 2020-07-27 Abraxis Bioscience, Llc Terapinių agentų deriniai bei įvedimo būdai ir kombinuotas gydymas
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
JP2011500046A (ja) * 2007-10-19 2011-01-06 ファルマ・マール・ソシエダード・アノニマ Et−743治療のための予後分子マーカー
AU2011232862B2 (en) 2010-03-29 2016-03-03 Abraxis Bioscience, Llc Methods of enhancing drug delivery and effectiveness of therapeutic agents
SG10201906075VA (en) 2010-03-29 2019-08-27 Abraxis Bioscience Llc Methods of treating cancer
NZ706745A (en) 2010-06-04 2017-01-27 Abraxis Bioscience Llc Methods of treatment of pancreatic cancer
US20180085377A1 (en) * 2015-04-22 2018-03-29 Syn-Nat Products Enterprise LLC Co-crystal composition and its pharmaceutical use
KR102198656B1 (ko) 2016-08-31 2021-01-05 후지필름 가부시키가이샤 항종양제, 항종양 효과 증강제 및 항종양용 키트
RU2646450C1 (ru) * 2017-05-11 2018-03-05 Владимир Михайлович Курусин Способ лечения предраковых и ранних стадий раковых заболеваний желудка
WO2019146130A1 (ja) 2018-01-29 2019-08-01 富士フイルム株式会社 胆道がん用抗腫瘍剤および胆道がんの処置方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4328229A (en) 1978-03-29 1982-05-04 Taiho Pharmaceutical Company Limited Anti-cancer composition for delivering 5-fluorouracil to cancer tissues
US5534513A (en) 1991-09-05 1996-07-09 Taiho Pharmaceutical Company, Ltd. Antitumor potentiator and antitumor composition
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents

Also Published As

Publication number Publication date
MXPA03007989A (es) 2003-12-04
NO20033910L (no) 2003-10-23
US6770653B2 (en) 2004-08-03
IL157357A0 (en) 2004-02-19
WO2002076459A1 (en) 2002-10-03
CZ20032266A3 (cs) 2004-02-18
ZA200306541B (en) 2004-11-22
CA2439676A1 (en) 2002-10-03
SK10602003A3 (en) 2004-10-05
PL363967A1 (en) 2004-11-29
KR20030081496A (ko) 2003-10-17
EP1368034A1 (en) 2003-12-10
RU2003129527A (ru) 2005-03-10
EE200300429A (et) 2003-12-15
US20020173482A1 (en) 2002-11-21
YU69903A (sh) 2006-08-17
JP2005506294A (ja) 2005-03-03
HUP0303466A3 (en) 2005-02-28
HRP20030801A2 (en) 2004-08-31
RU2284184C2 (ru) 2006-09-27
NO20033910D0 (no) 2003-09-04
HUP0303466A2 (hu) 2004-01-28
BR0207443A (pt) 2004-04-06

Similar Documents

Publication Publication Date Title
IS6925A (is) Aðferð og skömmtunarform til meðhöndlunar æxla með gjöf tegafúrs, úracíls, fólínsýru, paclítaxels og karbóplatíns
WO2002062763A3 (en) Inhibition of raf kinase using quinolyl isoquinolyl or pyridyl ureas
WO2003080582A3 (de) Fredericamycin-derivate
WO2002085857A3 (en) Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
IL163090A (en) Nicotinamide derivates, pharmaceutical compositions comprising them and their use for manufacture of medicaments useful as p38 inhibitors
DK1519724T3 (da) Fredericamycin-derivater som lægemidler til behandling af tumorer
HK1062440A1 (en) Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors
ATE454378T1 (de) Verbindungen, die sich als inhibitoren vonjak und anderen proteinkinasen eignen
IL164135A (en) 4-anilino quinazoline derivatives as antiproliferative agents, process for their preparation, pharmaceutical compositions containing such derivatives and use thereof for the preparation of medicaments for the treatment of cancer
CY1106766T1 (el) Παραγωγα πυριδινης ως αναστολεις raf κινασης
WO2005110994A3 (en) Substituted pyrazolyl urea derivatives useful in the treatment of cancer
DE60332629D1 (de) Phenyl-(4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yi)aminderivate
DK1200412T3 (da) Antiproliferative imidazolforbindelser
NO20070514L (no) Pyrrolotriazin kinase inhibitorer
ATE380807T1 (de) N-oxid von n-phenyl-2-pyrimidinaminderivaten
WO2003084539A3 (en) New pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
ATE408601T1 (de) Fredericamycin-derivate
DE60215178D1 (de) Quinolin-derivate und ihre verwendung als inhibitoren der tyrosine kinase
CY1108395T1 (el) Ουσια επαυξησης της δρασης εναντι ογκων και παραγοντας εναντι ογκων
DE60315479D1 (de) Pyrimidinamid derivate und deren verwendung
WO2004073615A3 (en) Deazaflavin compounds and methods of use thereof
ATE336489T1 (de) Stickstoff enthaltende heterozyklen und ihre verwendung als raf inhibitoren
AU2003245989A8 (en) Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
NO20034690D0 (no) Fremgangsmåte for behandling av tumorer ved administrering av tegafur, uracil, folinsyre og cyklofosfamid
ITRM20030442A0 (it) Composizione farmaceutica (stressen) per il trattamento di iperomocisteinemia.